Literature DB >> 7893896

Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis.

A Paugam, J Dupouy-Camet, P Blanche, J P Gangneux, C Tourte-Schaefer, D Sicard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7893896     DOI： 10.1093/clinids/19.5.975-a

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  38 in total

1.  Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.

Authors:  M Del Poeta; D L Toffaletti; T H Rude; C C Dykstra; J Heitman; J R Perfect
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

2.  G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

Authors:  Laura Rodero; Emilia Mellado; A Carolina Rodriguez; Angela Salve; Liliana Guelfand; Pedro Cahn; Manuel Cuenca-Estrella; Graciela Davel; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  A case report of pulmonary cryptococcosis presenting as endobronchial obstruction.

Authors:  Qing Zhou; Bijie Hu; Changzhou Shao; Chunmei Zhou; Xing Zhang; Dong Yang; Chun Li
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 4.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 5.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

6.  In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors:  M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

7.  Cell wall chitosan is necessary for virulence in the opportunistic pathogen Cryptococcus neoformans.

Authors:  Lorina G Baker; Charles A Specht; Jennifer K Lodge
Journal:  Eukaryot Cell       Date:  2011-07-22

8.  Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans.

Authors:  J Xu; C Onyewu; H J Yoell; R Y Ali; R J Vilgalys; T G Mitchell
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

9.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes.

Authors:  Edward Sionov; Hyeseung Lee; Yun C Chang; Kyung J Kwon-Chung
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.